Altimmune (ALT) Competitors $4.18 -0.08 (-1.88%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$4.15 -0.03 (-0.72%) As of 07:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALT vs. JANX, BHVN, ANIP, MESO, EWTX, TVTX, CVAC, PAHC, ABCL, and CALTShould you be buying Altimmune stock or one of its competitors? The main competitors of Altimmune include Janux Therapeutics (JANX), Biohaven (BHVN), ANI Pharmaceuticals (ANIP), Mesoblast (MESO), Edgewise Therapeutics (EWTX), Travere Therapeutics (TVTX), CureVac (CVAC), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry. Altimmune vs. Its Competitors Janux Therapeutics Biohaven ANI Pharmaceuticals Mesoblast Edgewise Therapeutics Travere Therapeutics CureVac Phibro Animal Health AbCellera Biologics Calliditas Therapeutics AB (publ) Janux Therapeutics (NASDAQ:JANX) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability. Does the media refer more to JANX or ALT? In the previous week, Altimmune had 5 more articles in the media than Janux Therapeutics. MarketBeat recorded 11 mentions for Altimmune and 6 mentions for Janux Therapeutics. Altimmune's average media sentiment score of 0.77 beat Janux Therapeutics' score of 0.57 indicating that Altimmune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Altimmune 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is JANX or ALT more profitable? Janux Therapeutics has a net margin of 0.00% compared to Altimmune's net margin of -451,200.00%. Janux Therapeutics' return on equity of -9.29% beat Altimmune's return on equity.Company Net Margins Return on Equity Return on Assets Janux TherapeuticsN/A -9.29% -8.89% Altimmune -451,200.00%-65.44%-58.43% Do institutionals & insiders hold more shares of JANX or ALT? 75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 29.4% of Janux Therapeutics shares are held by insiders. Comparatively, 4.1% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend JANX or ALT? Janux Therapeutics presently has a consensus price target of $91.89, suggesting a potential upside of 256.71%. Altimmune has a consensus price target of $18.20, suggesting a potential upside of 335.41%. Given Altimmune's higher possible upside, analysts plainly believe Altimmune is more favorable than Janux Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.08Altimmune 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75 Which has stronger valuation & earnings, JANX or ALT? Janux Therapeutics has higher revenue and earnings than Altimmune. Janux Therapeutics is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanux Therapeutics$10.59M143.93-$68.99M-$1.36-18.94Altimmune$20K16,951.99-$95.06M-$1.26-3.32 Which has more risk and volatility, JANX or ALT? Janux Therapeutics has a beta of 2.86, meaning that its stock price is 186% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. SummaryJanux Therapeutics beats Altimmune on 10 of the 17 factors compared between the two stocks. Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALT vs. The Competition Export to ExcelMetricAltimmuneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$345.52M$2.44B$5.61B$9.29BDividend YieldN/A1.79%4.23%4.03%P/E Ratio-3.329.1428.5419.58Price / Sales16,951.99679.15429.2495.01Price / CashN/A164.3436.0257.93Price / Book2.404.608.145.54Net Income-$95.06M$30.99M$3.24B$257.73M7 Day Performance-11.81%-1.81%0.18%-0.08%1 Month Performance-39.16%5.73%5.96%8.09%1 Year Performance-48.40%-7.03%26.24%13.02% Altimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTAltimmune2.1939 of 5 stars$4.18-1.9%$18.20+335.4%-47.1%$345.52M$20K-3.3250JANXJanux Therapeutics2.5345 of 5 stars$23.96-2.0%$95.25+297.5%-40.7%$1.42B$10.59M-17.6230BHVNBiohaven3.3466 of 5 stars$13.81-5.6%$58.46+323.3%-65.5%$1.41BN/A-1.48239News CoverageANIPANI Pharmaceuticals3.7256 of 5 stars$64.91-0.6%$80.13+23.4%+1.2%$1.41B$614.38M-51.11600News CoverageAnalyst RevisionMESOMesoblast2.1957 of 5 stars$10.53-1.4%$18.00+70.9%+43.3%$1.35B$5.90M0.0080EWTXEdgewise Therapeutics1.4594 of 5 stars$12.61-3.2%$40.00+217.2%-41.5%$1.33BN/A-8.1460TVTXTravere Therapeutics3.7938 of 5 stars$14.61-2.7%$32.14+120.0%+67.0%$1.30B$273.53M-5.20460Analyst RevisionCVACCureVac4.7246 of 5 stars$5.41-0.7%$6.83+26.3%+50.3%$1.21B$523.70M5.88880Positive NewsPAHCPhibro Animal Health3.9968 of 5 stars$29.90+6.8%$24.40-18.4%+73.6%$1.21B$1.02B38.331,940Gap UpHigh Trading VolumeABCLAbCellera Biologics2.2789 of 5 stars$4.03+6.1%$7.50+86.1%+23.1%$1.20B$28.83M-7.20500Analyst ForecastGap UpHigh Trading VolumeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180 Related Companies and Tools Related Companies Janux Therapeutics Alternatives Biohaven Alternatives ANI Pharmaceuticals Alternatives Mesoblast Alternatives Edgewise Therapeutics Alternatives Travere Therapeutics Alternatives CureVac Alternatives Phibro Animal Health Alternatives AbCellera Biologics Alternatives Calliditas Therapeutics AB (publ) Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALT) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALT Stock Alerts